NCT03826940View on ClinicalTrials.gov

From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 19, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

August 31, 2020

Conditions
Autism Spectrum DisorderNeurofibromatosis 1
Interventions
DRUG

Lovastatin 60 MG

60 MG Lovastatin per day for 3 consecutive days

DRUG

Placebos

60 MG Placebo per day for 3 consecutive days

Trial Locations (1)

3000-043

ICNAS, Coimbra

All Listed Sponsors
lead

University of Coimbra

OTHER

NCT03826940 - From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 | Biotech Hunter | Biotech Hunter